PEOPLE INTERVIEWED

An immigrant from New Delhi, India, Udit is an accomplished executive who has dedicated his career to improving health for people globally, bringing more than 20 years’ experience in healthcare and the life sciences. After Udit became CEO in 2014, he and his MilliporeSigma team developed and executed a growth strategy that included the 2015 acquisition of chemicals and technology giant Sigma-Aldrich. Udit architected and led this merger — the largest acquisition in the history of Merck KGaA, Darmstadt, Germany and one of the largest ever in the life science industry.

Today, Udit continues to lead the business through a strategic transformation that has made MilliporeSigma a top-three player in the industry and an employer of choice in many regions where it operates around the world. MilliporeSigma, based in Burlington, Massachusetts, was named to The Boston Globe's annual "Top Places to Work" list in 2016 and 2017, and received an exclusive certification as a top employer in North America by the independent Top Employers Institute in 2018 for the second year in a row. Also under Udit’s leadership, MilliporeSigma has earned several prestigious awards for innovation, including the R&D 100 Award for Top Innovations in 2016; a Life Science Industry Award by BioInformatics in 2016; and an R&D 100 Award for Corporate Responsibility in 2017.

Udit has earned a well-deserved reputation for driving business growth and turnarounds, as well as building high-performing teams. Previously, he led the company’s global Consumer Health business, where his team more than doubled the profitability of the business, making it the fastest-growing sector within Merck KGaA, Darmstadt, Germany.

Prior to Merck KGaA, Darmstadt, Germany, Udit served in a range of leadership positions at Novartis, a Swiss multinational pharmaceutical company. In addition to leading Corporate Strategy and Global Public Health and Market Access for Vaccines and Diagnostics, he also served as president of the Australia Pharma business. During his tenure, this subsidiary became the fastest-growing business within Novartis. Earlier in his career, Udit held senior positions in the healthcare, consumer and non-profit practices at McKinsey & Company, a global strategy and consulting company.

A chemical engineer by training, Udit earned a bachelor of science degree from the University of Delaware and a doctor of philosophy degree (Ph.D.) from Princeton University. He started his career as a research engineer fellow at Merck & Co, Inc., Kenilworth, NJ, where he worked on vaccines and small molecules. He has received multiple honors and awards, including nationally competitive, recognized fellowships at Merck & Co., Inc., Kenilworth, NJ; DuPont and Mitsubishi. He serves on the boards of the Greater Boston Chamber of Commerce and the Massachusetts High Technology Council, as Vice Chairman; he is also a member of the Advisory Council at Princeton University’s Department of Chemical Engineering.

Udit was named “CEO of the Year” by CPhI Pharma in 2016 and was also recognized for his strategic leadership by PharmaVOICE 100 in its list of top influencers for 2016. He is a frequent keynote speaker, representing the company at global investor conferences and industry congresses. Most recently, he addressed BioAsia in India; Societe de Chimie, University of Delaware – Gerster Lecture; and the Drug, Chemical and Associated Technologies Association, among others.

Most recently, Bulpin was Head of the Process Solutions Strategic Marketing & Innovation (SMI) team for Life Science. Prior to that, Bulpin served as Executive Vice President of Process Solutions for MilliporeSigma. Bulpin joined Millipore in 2006 as Vice President for the Upstream Processing business and later assumed leadership of the Services and Solutions business.

Following the company's acquisition by Merck KGaA, Darmstadt, Germany in 2010, he served as Global Head of Sales for the Pharmaceutical Chemical Solutions business. Prior to joining Millipore, Andrew worked at Serologicals Corporation in a number of sales and marketing roles, both in the U.S. and Europe.

Andrew holds a Ph.D. in Organic Chemistry from the Université de Caen, France, a Master of Business Administration degree from the University of Strathclyde, Scotland, and a Bachelor degree from the University of Sussex, England. He also worked as a Post-Doctoral Research Fellow at the Australian National University, Australia.

Having served over 10 years with Pall, Eric is currently a Sr. Scientist in the Scientific Laboratory Services (SLS) Continuous BioProcessing technical team supporting customer opportunities to investigate continuous technologies through consultation and trial work with a specific focus around continuous chromatography.

C-SOPS focuses on the science based development of pharmaceutical products and processes. C-SOPS has been directly involved in working with major pharmaceutical companies and the FDA on the first processes for continuous manufacturing of pharmaceutical solid dose products.

Paul has a Masters in Chemical Engineering with a Biotechnology Focus from Cornell University.

He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the US Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on marketing, pricing and channel management topics, and teaches at Johns Hopkins University and American University: Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication. In 1989 he co-founded BioPlan Associates, Inc. He has launched and managed marketing programs for product lines ranging from $500k to $500 million.

Most recently, Mr. Malhotra gained experience as Director of Corporate Research & Technology for Morgan Adhesives Co. (MACtac), a $500 million international division of Bemis Co., manufacturer of packaging films and pressure sensitive products, from 1991-1996. For The Sherwin Williams Company, a $6.1 billion dollar architectural, industrial and automotive coatings company, Mr. Malhotra worked as the:

• Business Development Project Director (1987 -1991)
• Director, Process Engineering (1985 -1987)
• Plant Manager, Antioxidants and Resins -Fords, NJ (1983 -1985)
• Technical Director, Antioxidants and Resins -Fords, NJ (1981 -1983)
• Production Area Manager, Corrosion Inhibitors & Intermediates -Cincinnati, OH(1979 -1981)
• Group Leader/Senior Process Engineer (1973 -1979)
• From 1971 to 1973, Mr. Malhotra was an Environmental Protection Engineer for the State of Illinois EPA, and before that, he was a Process Engineer for EXXON.

He managed a team responsible for the field-based applications development and support of Pall’s direct flow filtration and tangential flow filtration technologies. Additionally, Kevin is the lead for the Western Hemisphere Depth filtration technical team. Prior to joining Pall, Kevin worked at The Chisholm Corporation, which was a regional distributor for Pall where he was a sales specialist. Kevin has a BS in Zoology from the University of Rhode Island in Kingston, RI.

In his role, Jonathan is responsible for design, development and delivery of next generation manufacturing strategies and advanced process/analytical development methodologies to improve efficiency and effectiveness of development capabilities and manufacturing performances. Before joining Merck KGaA, Darmstadt, Germany, Jonathan held leadership development positions at Boehringer Ingelheim as Head of Global Bioprocess Science and at Allergan as Head of Process Development. Jonathan has a Master of Science in Biochemical Engineering from University College London and a PhD in Biochemical Engineering from University of Birmingham.

Kate’s team is providing market leading solutions to all major biopharmaceutical companies and many CMOs globally.

Kate has MBA from Harvard Business School, PhD in Biochemistry from Tufts University and BS in Chemistry from Moscow State University, Russia.

From 2015-2017, Verlenden lead the Filtration and Chromatography business within Process Solutions. Prior to that, he held multiple roles in MilliporeSigma‘s Global Pharma Processing Commercial organization, including Senior Director of Global Key Accounts. He started his career with Millipore in 2000 in a technical role supporting the product adoption aspects of the company’s sales cycle.

Before joining the company, Verlenden worked in the vaccine industry. This included roles at Wyeth Lederlee Pharmaceuticals working on influenza vaccines and Immune Response Corporation developing HIV vaccines.

Her career has spanned multiple industries from Xerox immediately after gradution, then moving on to bring hollow fiber UF systems to the US market for drinking water and waste water reuse applications at Ionics and Koch Membrane Systems. In 2006, Merrilee began her career at MilliporeSigma* as the Product Manager for the Millistak+® product line. Throughout her 11 years she has managed multiple product lines including clarification, aseptic, virus filtration, and Single Use & Systems. Merrilee has served as the Head of Next Generation Bioprocessing since January, 2017.

* The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. And Canada.